Open Access Articles- Top Results for Selumetinib


File:Selumetinib skeletal.svg
Systematic (IUPAC) name
Clinical data
  • Investigational
PubChem CID 10127622
ChemSpider 8303141 7pxY
KEGG D09666 7pxY
ChEMBL CHEMBL1614701 7pxY
Synonyms AZD6244, ARRY-142886
Chemical data
Formula C17H15BrClFN4O3
457.68 g/mol
 14pxY (what is this?)  (verify)

Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC).

Mechanism of action

The gene BRAF is part of the MAPK/ERK pathway, a chain of proteins in cells that communicates input from growth factors. Activating mutations in the BRAF gene, primarily V600E (meaning that the amino acid valine in position 600 is replaced by glutamic acid), are associated with lower survival rates in patients with papillary thyroid cancer. Another type of mutation that leads to undue activation of this pathway occurs in the gene KRAS and is found in NSCLC. A possibility of reducing the activity of the MAPK/ERK pathway is to block the enzyme MAPK kinase (MEK), immediately downstream of BRAF, with the drug selumetinib. More specifically, selumetinib blocks the subtypes MEK1 and MEK2 of this enzyme.[1]

Possible uses

In addition to thyroid cancer, BRAF-activating mutations are prevalent in melanoma (up to 59%), colorectal cancer (5–22%), serous ovarian cancer (up to 30%), and several other tumor types.[2]

Selumetinib has also been shown to inhibit growth of GNAQ mutated uveal melanoma cell lines.[3] Furthermore, preliminary results suggest that selumetinib treatment of uveal melanoma patients can result in tumor shrinkage as the consequence of sustained inhibition of ERK phosphorylation.[4]

KRAS mutations appear in 20 to 30% of NSCLC cases and about 40% of colorectal cancer.[1]

A Phase II clinical trial about selumetinib in NSCLC has been completed in September 2011;[5] one about cancers with BRAF mutations is ongoing as of June 2012.[6]


  1. ^ a b Troiani, T.; Vecchione, L.; Martinelli, E.; Capasso, A.; Costantino, S.; Ciuffreda, L. P.; Morgillo, F.; Vitagliano, D.; d'Aiuto, E.; De Palma, R.; Tejpar, S.; Van Cutsem, E.; De Lorenzi, M.; Caraglia, M.; Berrino, L.; Ciardiello, F. (2012). "Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase a activation in human lung and colorectal cancer cells". British Journal of Cancer 106 (10): 1648–1659. PMC 3349172. PMID 22569000. doi:10.1038/bjc.2012.129.  edit
  2. ^ Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J. (2002). "Mutations of the BRAF gene in human cancer". Nature 417 (6892): 949–954. PMID 12068308. doi:10.1038/nature00766.  edit
  3. ^ "Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance". Clinical Cancer Research. Jul 1, 2012. doi:10.1158/1078-0432.CCR-11-3086. 
  4. ^ "Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma". 2012. 
  5. ^ Clinical trial number NCT00890825 for "Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients" at
  6. ^ Clinical trial number NCT00888134 for "AZD6244 in Cancers With BRAF Mutations" at

Further reading